Portfolio Finder


Atriva Therapeutics stands for the next generation of antiviral therapies. MEK Inhibitors have high potential as truly efficacious and safe antiviral drugs to address the urgent need e.g. for a novel, broadly active influenza therapy.

HTGF-Manager: Dr. Frank Hensel
Added to portfolio 27. Dec 2016

MYR Exit

MYR develops a novel, peptide-based, first-in-class drug (entry inhibitor) for the treatment of chronic hepatitis B and Delta infections. Clinical phase IIb currently in preparation.

HTGF-Manager: Dr. Bernd Goergen
In portfolio 21. Jan 2011 – 09. Dec 2020